Axsome Historical Income Statement
| AXSM Stock | USD 120.51 1.26 1.03% |
Historical analysis of Axsome Therapeutics income statement accounts such as Interest Expense of 3.3 M, Selling General Administrative of 431.9 M or Other Operating Expenses of 699.6 M can show how well Axsome Therapeutics performed in making a profits. Evaluating Axsome Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Axsome Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Axsome Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Axsome Therapeutics is a good buy for the upcoming year.
Axsome |
About Axsome Income Statement Analysis
Axsome Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Axsome Therapeutics shareholders. The income statement also shows Axsome investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Axsome Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Axsome Therapeutics. It is also known as Axsome Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Axsome Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Axsome Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.At this time, Axsome Therapeutics' Gross Profit is very stable compared to the past year. As of the 28th of March 2025, Cost Of Revenue is likely to grow to about 35 M, though Operating Income is likely to grow to (266.5 M).
| 2022 | 2023 | 2024 | 2025 (projected) | Interest Expense | 7.3M | 6.5M | 6.6M | 3.3M | Depreciation And Amortization | 5.6M | 6.8M | 7.9M | 8.3M |
Axsome Therapeutics income statement Correlations
Click cells to compare fundamentals
Axsome Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Axsome Therapeutics income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Depreciation And Amortization | 77.7K | 1.2M | 5.6M | 6.8M | 7.9M | 8.3M | |
| Interest Expense | 2.6M | 5.7M | 7.3M | 6.5M | 6.6M | 3.3M | |
| Selling General Administrative | 28.9M | 66.6M | 124.0M | 222.8M | 411.4M | 431.9M | |
| Other Operating Expenses | 99.1M | 124.7M | 226.5M | 502.4M | 666.3M | 699.6M | |
| Operating Income | (99.1M) | (124.7M) | (176.5M) | (231.8M) | (280.6M) | (266.5M) | |
| Ebit | (99.1M) | (124.7M) | (179.8M) | (231.8M) | (208.6M) | (198.2M) | |
| Research Development | 70.2M | 58.1M | 57.9M | 97.9M | 187.1M | 196.4M | |
| Ebitda | (99.1M) | (123.6M) | (174.2M) | (225.0M) | (280.6M) | (266.5M) | |
| Total Operating Expenses | 99.1M | 124.7M | 221.3M | 476.4M | 633.0M | 664.6M | |
| Income Before Tax | (102.9M) | (130.4M) | (187.1M) | (238.3M) | (287.1M) | (272.8M) | |
| Total Other Income Expense Net | (3.8M) | (5.7M) | (7.3M) | (6.5M) | (6.6M) | (6.2M) | |
| Net Income | (105.4M) | (134.9M) | (197.8M) | (239.2M) | (287.2M) | (272.9M) | |
| Income Tax Expense | 2.5M | 4.5M | 10.6M | 960K | 85K | 80.8K | |
| Gross Profit | (77.7K) | (1.2M) | 44.8M | 244.5M | 352.4M | 370.0M | |
| Net Income From Continuing Ops | (103.0M) | (130.4M) | (187.1M) | (239.2M) | (287.2M) | (272.9M) | |
| Cost Of Revenue | 77.7K | 1.2M | 5.2M | 26.1M | 33.3M | 35.0M | |
| Net Income Applicable To Common Shares | (68.3M) | (102.9M) | (130.4M) | (187.1M) | (168.4M) | (160.0M) | |
| Net Interest Income | (2.6M) | (5.7M) | (7.3M) | (6.5M) | (6.6M) | (6.2M) | |
| Non Operating Income Net Other | 1.7M | (1.2M) | (3.8M) | (5.7M) | (5.1M) | (4.9M) | |
| Reconciled Depreciation | 77.7K | 1.2M | 4.1M | 6.8M | 8.0M | 8.4M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.99) | Revenue Per Share | Quarterly Revenue Growth 0.66 | Return On Assets | Return On Equity |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.